No Data
Dezhan Healthcare (000813.SZ): has not collaborated with the viral marketing company.
Gelonghui November 14th | dezhan healthcare (000813.SZ) stated on the investor interaction platform that the company is currently not cooperating with explosive advertising and marketing companies.
Express News | Dezhan Healthcare: The portion of the company's shares held by shareholder Merrill Lynch will be subject to judicial enforcement.
dezhan healthcare (000813.SZ): has repurchased 1.16% of the shares accumulated.
格隆汇 November 4th | dezhan healthcare (000813.SZ) announced that as of October 31, 2024, the company has repurchased a total of 25,037,500 shares of the company through the special securities account for share repurchase by centralized bidding trading method, accounting for 1.16% of the company's current total share capital. The highest fill price was 3.03 yuan/share, the lowest fill price was 2.39 yuan/share, and the total fill amount was 62,550,587.00 yuan (excluding transaction fees).
Dezhan Health: Report for the third quarter of 2024
Dezhan Healthcare (000813.SZ): The net income for the first three quarters was 8.0896 million yuan, a year-on-year decrease of 86.82%.
Galaxy Health (000813.SZ) released its third quarter report for 2024 on October 30th, announcing that the company achieved revenue of 0.354 billion yuan in the first three quarters, a year-on-year increase of 5.77%; the net income attributable to shareholders of the listed company was 8.0896 million yuan, a year-on-year decrease of 86.82%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 4.6112 million yuan, a year-on-year increase of 123.13%; and the basic earnings per share were 0.0037 yuan.
Dezhan Healthcare (000813.SZ): Promote the pilot production and conversion of Simecraglutepeptide raw materials and recombinant human collagen raw materials as soon as possible.
Dezhan Healthcare (000813.SZ) stated during an investor relations event on September 23 that in addition to 'Ale' and 'Nile', the company will further explore the potential of its existing products, combining current policies and market conditions with product approvals, and select products with market potential to resume production, such as sodium warfarin tablets and hydrochloride quetiapine tablets, enriching the company's pipeline of chemical pharmaceutical products. In addition, effort will be made to expedite the conversion of early-stage research projects into income, and to advance the pilot production of Simvastatin raw materials and recombinant human collagen raw materials. Furthermore, the company currently has ample cash reserves and plans to achieve synergies through mergers and acquisitions.
No Data
No Data